Evidence map›Paper›PMID 41868663›Full record

ArticleAmerican journal of cancer research2026

SSTR2-targeting therapy in EBV-positive and EBV-negative metastatic nasopharyngeal carcinoma.

Chen-Yang Huang, Chiao-Yun Lin, Kar-Wai Lui, Yin-Kai Chao, Li-Yu Lee, Yen-Lin Huang, Chia-Hsun Hsieh, Hsien-Chi Fan, An-Chi Lin, Kai-Ping Chang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chen-Yang HuangDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Chiao-Yun LinGynecologic Cancer Research Center, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Kar-Wai LuiDepartment of Medical Imaging and Intervention, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Yin-Kai ChaoDivision of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Li-Yu LeeDepartment of Pathology, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Yen-Lin HuangDepartment of Pathology, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Chia-Hsun HsiehDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Hsien-Chi FanDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
An-Chi LinDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Kai-Ping ChangDepartment of Otolaryngology-Head and Neck Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Chien-Yu LinDepartment of Radiation, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Hung-Ming WangDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Yu-Sun ChangDepartment of Microbiology and Immunology, Chang Gung University Taoyuan 33305, Taiwan.
Hsin-Pai LiDepartment of Microbiology and Immunology, Chang Gung University Taoyuan 33305, Taiwan.
Cheng-Lung HsuDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) - associated malignancy prevalent in South Asia, and somatostatin receptors (SSTRs), particularly SSTR2, are expressed in NPC and other solid tumors, suggesting a potential therapeutic target. We observed abundant SSTR2 expression in NPC cell lines and patient-derived xenografts (PDXs). In the EBV-negative PDX-Li41 model, treatment with the SSTR2 agonist octreotide (OCT) significantly inhibited xenograft growth and showed additive effects with chemotherapy; transcriptomic and protein analyses revealed heterogeneous regulation of cell-cycle-related genes, upregulation of DNA replication pathways, downregulation of cell-signaling and neurotransmitter-release pathways, and reduced expression of CDK6, NF-κB, E2F1, CDK2, and BIRC5. In contrast, OCT did not suppress tumor growth in the EBV-positive PDX-B13 model, prompting the development of an octreotide-monomethyl auristatin E (OCT-MMAE) peptide-drug conjugate, which demonstrated efficient cellular internalization, a low IC50 (≈ 10

Indexed as

Epstein Barr virusNasopharyngeal carcinomapatient derived xenograftpeptide-drug conjugateSSTR2

Identifiers

PMID41868663
PMCPMC13000136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.